Evolution and Treatments of Chronic Inflammatory Systemic Diseases
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON · Dec 5, 2019
Trial Information
Current as of May 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at chronic inflammatory diseases (CID) like Inflammatory Bowel Diseases (IBD), rheumatoid arthritis, and chronic skin conditions such as psoriasis. Researchers want to understand how these conditions are connected and how they can affect each other. The goal is to create a better understanding of these diseases, as many patients with one inflammatory condition may also experience other related issues. Currently, there's no shared database in France that collects information on these diseases, so this study aims to fill that gap.
To be eligible for the trial, participants should be patients treated for IBD (like Crohn's disease or ulcerative colitis), chronic inflammatory rheumatism (like rheumatoid arthritis or spondyloarthritis), or chronic inflammatory skin diseases (like psoriasis or Verneuil's disease) at the Besançon University Hospital. Participants can expect to contribute to valuable research that may help improve treatment options for themselves and others. It’s important to note that individuals who are in emergency situations or unable to provide consent cannot participate in this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients treated for IBD (MC, UC or indeterminate colitis) in the gastroenterology department of Besançon University Hospital
- • Subject meeting the clinical, morphological and histological diagnostic criteria for MC, UC or indeterminate colitis or
- • Patients treated for chronic inflammatory rheumatism (RA, SpA, PsA) in the rheumatology department of the University Hospital of Besançon Subject meeting the ACR 2010 classification criteria of RA or modified New York criteria of Ankylosing spondylitis or ASAS criteria of axial or peripheral SpA or CASPAR criteria of PsA or
- • Patients treated for chronic inflammatory skin disease (Psoriasis, Verneuil's disease) in the dermatology department of the University Hospital of Besançon
- Exclusion Criteria:
- • Opposition of the patient
- • Patients in emergency situation, persons deprived of their liberty, protected minors or adults.
About Centre Hospitalier Universitaire De Besancon
The Centre Hospitalier Universitaire de Besançon (CHU de Besançon) is a leading academic medical center located in Besançon, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Besançon focuses on a wide range of medical disciplines, fostering collaboration between healthcare professionals and researchers to develop new therapeutic strategies and improve patient outcomes. With a commitment to rigorous scientific standards and ethical practices, the institution plays a vital role in translating research findings into practical applications, ultimately enhancing the quality of care provided to the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Besançon, , France
Besançon, , France
Patients applied
Trial Officials
Clément Prati, Prof.
Principal Investigator
CHU Besançon
Lucine Vuitton, MD
Principal Investigator
CHU Besançon
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials